IBDEI0CW ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,5786,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5786,1,3,0)
 ;;=3^277.30
 ;;^UTILITY(U,$J,358.3,5786,1,4,0)
 ;;=4^AMYLOIDOSIS NOS
 ;;^UTILITY(U,$J,358.3,5786,2)
 ;;=^334185
 ;;^UTILITY(U,$J,358.3,5787,0)
 ;;=277.31^^28^382^3
 ;;^UTILITY(U,$J,358.3,5787,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5787,1,3,0)
 ;;=3^277.31
 ;;^UTILITY(U,$J,358.3,5787,1,4,0)
 ;;=4^FAM MEDITERRANEAN FEVER
 ;;^UTILITY(U,$J,358.3,5787,2)
 ;;=^189367
 ;;^UTILITY(U,$J,358.3,5788,0)
 ;;=277.39^^28^382^2
 ;;^UTILITY(U,$J,358.3,5788,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5788,1,3,0)
 ;;=3^277.39
 ;;^UTILITY(U,$J,358.3,5788,1,4,0)
 ;;=4^AMYLOIDOSIS,OTHER
 ;;^UTILITY(U,$J,358.3,5788,2)
 ;;=^334034
 ;;^UTILITY(U,$J,358.3,5789,0)
 ;;=446.21^^28^382^4
 ;;^UTILITY(U,$J,358.3,5789,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5789,1,3,0)
 ;;=3^446.21
 ;;^UTILITY(U,$J,358.3,5789,1,4,0)
 ;;=4^GOODPASTURE'S SYNDROME
 ;;^UTILITY(U,$J,358.3,5789,2)
 ;;=^52601^583.81
 ;;^UTILITY(U,$J,358.3,5790,0)
 ;;=580.0^^28^382^8
 ;;^UTILITY(U,$J,358.3,5790,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5790,1,3,0)
 ;;=3^580.0
 ;;^UTILITY(U,$J,358.3,5790,1,4,0)
 ;;=4^NEPHRITIS,AC PROLIFERATIVE
 ;;^UTILITY(U,$J,358.3,5790,2)
 ;;=^270338
 ;;^UTILITY(U,$J,358.3,5791,0)
 ;;=580.4^^28^382^9
 ;;^UTILITY(U,$J,358.3,5791,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5791,1,3,0)
 ;;=3^580.4
 ;;^UTILITY(U,$J,358.3,5791,1,4,0)
 ;;=4^NEPHRITIS,AC RAPIDLY PROGR
 ;;^UTILITY(U,$J,358.3,5791,2)
 ;;=^270339
 ;;^UTILITY(U,$J,358.3,5792,0)
 ;;=580.9^^28^382^7
 ;;^UTILITY(U,$J,358.3,5792,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5792,1,3,0)
 ;;=3^580.9
 ;;^UTILITY(U,$J,358.3,5792,1,4,0)
 ;;=4^NEPHRITIS,AC NOS
 ;;^UTILITY(U,$J,358.3,5792,2)
 ;;=^270342
 ;;^UTILITY(U,$J,358.3,5793,0)
 ;;=582.0^^28^382^14
 ;;^UTILITY(U,$J,358.3,5793,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5793,1,3,0)
 ;;=3^582.0
 ;;^UTILITY(U,$J,358.3,5793,1,4,0)
 ;;=4^NEPHRITIS,CHR PROLIFERATIVE
 ;;^UTILITY(U,$J,358.3,5793,2)
 ;;=^270347
 ;;^UTILITY(U,$J,358.3,5794,0)
 ;;=582.1^^28^382^12
 ;;^UTILITY(U,$J,358.3,5794,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5794,1,3,0)
 ;;=3^582.1
 ;;^UTILITY(U,$J,358.3,5794,1,4,0)
 ;;=4^NEPHRITIS,CHR MEMBRANOUS
 ;;^UTILITY(U,$J,358.3,5794,2)
 ;;=^24388
 ;;^UTILITY(U,$J,358.3,5795,0)
 ;;=582.2^^28^382^11
 ;;^UTILITY(U,$J,358.3,5795,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5795,1,3,0)
 ;;=3^582.2
 ;;^UTILITY(U,$J,358.3,5795,1,4,0)
 ;;=4^NEPHRITIS,CHR MEMBRANOPROLIF
 ;;^UTILITY(U,$J,358.3,5795,2)
 ;;=^24386
 ;;^UTILITY(U,$J,358.3,5796,0)
 ;;=582.4^^28^382^15
 ;;^UTILITY(U,$J,358.3,5796,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5796,1,3,0)
 ;;=3^582.4
 ;;^UTILITY(U,$J,358.3,5796,1,4,0)
 ;;=4^NEPHRITIS,CHR RAPID PROGR
 ;;^UTILITY(U,$J,358.3,5796,2)
 ;;=^270348
 ;;^UTILITY(U,$J,358.3,5797,0)
 ;;=582.81^^28^382^10
 ;;^UTILITY(U,$J,358.3,5797,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5797,1,3,0)
 ;;=3^582.81
 ;;^UTILITY(U,$J,358.3,5797,1,4,0)
 ;;=4^NEPHRITIS,CHR IN OTH DIS
 ;;^UTILITY(U,$J,358.3,5797,2)
 ;;=^270350
 ;;^UTILITY(U,$J,358.3,5798,0)
 ;;=582.9^^28^382^13
 ;;^UTILITY(U,$J,358.3,5798,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5798,1,3,0)
 ;;=3^582.9
 ;;^UTILITY(U,$J,358.3,5798,1,4,0)
 ;;=4^NEPHRITIS,CHR NOS
 ;;^UTILITY(U,$J,358.3,5798,2)
 ;;=^270351
 ;;^UTILITY(U,$J,358.3,5799,0)
 ;;=583.81^^28^382^5
 ;;^UTILITY(U,$J,358.3,5799,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5799,1,3,0)
 ;;=3^583.81
 ;;^UTILITY(U,$J,358.3,5799,1,4,0)
 ;;=4^NEPHRITIS IN OTH DIS
 ;;^UTILITY(U,$J,358.3,5799,2)
 ;;=^82243
 ;;^UTILITY(U,$J,358.3,5800,0)
 ;;=583.81^^28^382^16
 ;;
 ;;$END ROU IBDEI0CW
